NeuraLight ads

A major step toward a new era of precision mental health. Proud to announce our strategic partnership with Asha Neuromodulation Clinics (ANC), India's leading multi-center Deep TMS network. Together, wer'e taking an ambitious step toward transforming how mental health treatments are measured, evaluated, and personalized, combining ANCs clinical expertise with NeuraLight's AI-powered brain function biomarkers. Our shared vision is to make objective brain function measurement a fundamental part of mental healthcare, bringing greater precision to one of the largest unmet needs in global healthcare. For NeuraLight, this partnership reflects the scale of our ambition: to build the measurement layer for the future of brain health. Proud to join forces with Dr. M S Reddy, Dr Aswin Kumar Mudunuru and the entire ANC team to help shape the future of precision mental health. Full announcement in the comments.

648 patients. Nearly 3 years. No demonstrated clinical benefit. 24 patients. Just 28 days. A measurable signal of drug effect on brain function. At #MDS2026, two Parkinson’s trials presented in the same late-breaking session highlighted one of the biggest challenges in drug development: How do we know if a drug is actually changing brain function? While Biogen’s LUMA trial could not demonstrate a clinical benefit over placebo using conventional clinical scales, Arvinas presented promising results from its Phase 1 trial, where NeuraLight’s biomarkers detected changes in brain function in just 28 days, alongside changes in biological markers of drug activity. The signal was there. NeuraLight made sure it didn’t go undetected. Better measurements. Faster answers. A new era for brain health. Proud of our team and our partners for turning this vision into clinical evidence!

Today marked an exciting step toward a treatment that could do more than manage Parkinson’s symptoms, one designed to address the biology of the disease itself. At #MDS2026, Dr. Kyle Fraser, Director of Translational Sciences at Arvinas, presented new data from ARV-102, including results generated using NeuraLight biomarkers . ARV-102 is a particularly exciting program: a brain-penetrant PROTAC targeting LRRK2, one of the most compelling and well-validated targets in Parkinson’s disease. In just 28 days, NeuraLight’s biomarkers captured worsening brain function in placebo participants alongside improvement in patients treated with ARV-102 - highlighting both the potential of the program and the sensitivity of our technology to meaningful changes in brain function. It is rare and incredibly exciting to see an early-stage Parkinson’s program generate a potential functional signal like this. For us, it is even more meaningful that NeuraLight helped make that signal visible. Proud of our team, and grateful to be working alongside the outstanding team at Arvinas and everyone who made this work possible. And this is only the beginning.

Behind the scenes at #MDS2026.

So exciting to have Prof. Olivier Rascol, Head of NeuraLight’s Scientific Advisory Board, with us at the NeuraLight booth at #MDS2026 !! 🙌 Here with Edmund Ben-Ami, talking through some of the results we’re seeing across programs and let’s just say, there’s a lot we’re excited to share. Come see us at Booth 422 and hear what’s coming next!

It's so great to have such amazing partners as the team of Mission Therapeutics! Thank you Sarah Fritchley and Suhail Nurbhai MBChB MRCP(UK) for stopping by at the NeuraLight booth at #MDS2026, and for the continued partnership! We're proud to be a part of your multicenter MTX-325 program, with our precision #biomarkers, and so excited for what’s ahead together!